Research Paper Volume 16, Issue 10 pp 8772—8809
Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses
Figure 8. Prediction of immunotherapy by MPPS model. Survival analysis (A) and response to anti-PD-L1 therapy (B) between the high- and low-risk groups in advanced urothelial cancer (IMvigor210 cohort). Survival analysis (C) and response to anti-CTLA4 and anti-PD1 therapy (D) between the high- and low-risk groups in melanoma (GSE91061). Survival analysis (E) and response to anti-CTLA4 therapy (F) between the high- and low-risk groups in metastatic melanoma. Survival analysis (G) and response to anti-PD1 therapy (H) between the high- and low-risk groups in NSCLC (GSE126044). Survival analysis (I) and response to anti-PD-1/PD-L1 therapy (J) between the high- and low-risk groups in NSCLC (GSE135222). Survival analysis (K) and response to adoptive T cell therapy (L) between the high- and low-risk groups in melanoma. Survival analysis (M) and response to anti-PD-1 therapy (N) between the high- and low-risk groups in melanoma (GSE78220). (O) Difference of responder between low- and high-risk group of LUAD in TCGA. (P) Difference of benefits between low- and high-risk group of LUAD in TCGA.